Anna Sjöström at the research group Experimental and Clinical Neuroendocrinology, the Department of Molecular Medicine and Surgery, will defend her thesis "Severe COVID-19 and routine biomarker patterns" on November 24, ...
Nov 20, 2023
0
0
In the treatment of immune thrombocytopenia (ITP), glucocorticoids and IVIg are considered the primary therapeutic options. Typically, clinicians opt for either of these treatments when addressing ITP cases. The research ...
Oct 10, 2023
0
8
Aside from transfusions, there currently is no way to boost people's platelet counts, leaving them at risk for uncontrolled bleeding. Could something as simple as a dietary change raise platelet counts in people with low ...
Aug 23, 2023
0
15
Cedars-Sinai Guerin Children's investigators have advanced our understanding of the role that blood platelets play in Kawasaki disease, a serious illness that primarily affects children younger than 5 years old and causes ...
Jul 24, 2023
0
24
A new review paper titled "What is hemoglobin, albumin, lymphocyte, platelet (HALP) score? A comprehensive literature review of HALP's prognostic ability in different cancer types" has been published in Oncotarget
Mar 6, 2023
0
5
Patients taking efgartigimod, a drug being studied for use to treat chronic primary immune thrombocytopenia (ITP), exhibited a significantly greater improvement in platelet counts which are essential to clotting and stopping ...
Dec 10, 2022
0
69
Inflammation is the body's first line of defense, occurring as droves of immune cells rush to the site of injury or acute illness to make repairs and stem further damage.
Aug 22, 2022
1
1171
(HealthDay)—For adults with immune thrombocytopenia, the addition of mycophenolate mofetil to a glucocorticoid for first-line treatment is associated with fewer treatment failures and higher response rates than glucocorticoid-only ...
Sep 2, 2021
0
5
One test of both the power and hunger of any individual or organization is the ability to master any and every new, sufficiently advanced technological opportunity that urgently presents itself to the world at large. For ...
(HealthDay)—For patients with elevated lipoprotein(a) levels and established cardiovascular disease, hepatocyte-directed antisense oligonucleotide AKCEA-APO(a)-LRX (APO(a)-LRX) reduces lipoprotein(a) levels, according to ...
Jan 3, 2020
0
5
